cis-diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro

Cancer Immunology Immunotherapy

Volumn 47, Issue 4, 1998, Pages 233-241

  Okamoto, Masato ^a   Kasetani, Hirofumi ^a   Kaji, Ryoji ^a   Goda, Hisashi ^a   Ohe, Go ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 FU; Antitumor effect; Cisplatin; Cytokines; NK and LAK activities

Indexed keywords

CISPLATIN; COMPLEMENT; CYTOKINE; FLUOROURACIL; GAMMA INTERFERON; GANGLIOTETRAOSYLCERAMIDE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SPLEEN CELL; SURVIVAL TIME; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; CYTOKINES; FEMALE; FLUOROURACIL; G(M1) GANGLIOSIDE; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, NUDE; SALIVARY GLAND NEOPLASMS; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0032433804     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050526     Document Type: Article

References (31)

1. Alfieri AA, Hahn EW (1978) An in situ method for estimating cell survival in a solid tumor. Cancer Res 38:3006
2. Anderson LC, Nilsson K, Gahmberg CG (1979) K-562, a human erythroleukemic cell line. Int J Cancer 23:143
3. Boyum A (1967) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Invest 21:77
4. Broder S, Waldmann TA (1978) The suppressor-cell network in cancer. N Engl J Med 299:1281
5. Fidler IJ (1985) Macrophages and metastasis: a biological approach to cancer therapy. Presidental address. Cancer Res 45:4714
6. Fogh L, Lund RO (1957) Continuous cultivation of epithelial cell strain (FL) from human amniotic membrane. Proc Soc Exp Biol Med 94:532
7. Gazit Z, Kedar E (1994) Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mine. Cancer Immunol Immunother 39:243
8. Gollin FF, Ansfieid FJ, Brandenburg JH, Ramires G, Vermund H (1972) Combined therapy in advanced head and neck cancer: a randomized study. Am J Roentgenol 114:83
9. Harris J, Sengar D, Stewart T, Hyslop D (1976) The effect of immunosuppressive chemotherapy on immune function in patients with malignant desease. Cancer 37 [Suppl]:1058
10. Holcombe RF, Stewart RM, Betzing KW, Kannan K (1994) Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 38:394
11. Kiyohara T, Taniguchi K, Kubota S, Koga S, Sakuragi T, Saitoh Y (1988) Induction of lymphokine-activated killer-like cells by cancer chemotherapy. J Exp Med 168:2355
12. Klein E, Klein G, Nadkarni JS, Nadkari J, Wigzell H, Clifford P (1968) Surface IgM-Kapp specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300
13. Kleinerman ES, Zwelling LA, Muchmore AV (1980) Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Cancer Res 40:3099
14. Kuge S, Miura Y, Nakamura Y, Mitomi T, Habu S, Nishimura T (1995) Superantigen-induced human CD4 + helper/ killer T cell phenomenon. Selective induction of Th1 helper/ killer T cells and application to tumor immunotherapy. J Immunol 154:1777
15. Lamon EW, Gatti RA, Kiessling R, Fenyo EM (1975) Comparison ol the allospecific and viral-specific immune responses to irradiated versus formaldehyde-fixed allogeneic Molony lymphoma cells in CBA mine. Cancer Res 35:962
16. Lichtenstein AK, Daniela P (1986) Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum(II) in vivo and in vitro. Cancer Res 46:639
17. Okamoto M, Kaji R, Kasetani H, Yoshida H, Moriya Y, Saito M, Sato M (1993) Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J Immunother 13:232
18. 2+, protein kianse activity, and ATP contents of cicplatin-and rIFN-γ-treated non-adherent mononuclear cells. Biochem Int 26:1017
19. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M (1985) Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour 5-FU infusion and cisplatin. Cancer 55:1123
20. Ruff MR, Gifford GE (1981) Tumor necrosis factor: In: Pick E (ed) Lymphokines. Academic Press, New York, p 235
21. Sato M, Yoshida H, Urata M, Yanagawa T, Yura Y, Nitta T, Kobayasi S, Hayashi Y (1984) Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. Int J Oral Surg 13:35
22. Sato M, Yoshida H, Yanagawa T, Yura Y, Urata M, Atsumi M, Hayashi Y, Takegawa Y (1984) Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 13:7
23. Sato M, Hayashi Y, Yanagawa T, Yoshida H, Yura Y, Azuma M, Ueno A (1985) Intermediate-sized filaments and specific markers in a human salivary gland adenocarcinoma cell line and its nude mice tumors. Cancer Res 45:3878
24. Sato M, Harada K, Yoshida H, Yura Y, Azuma M, Iga H, Bando T, Kawamata H, Takagawa Y (1997) Therapy for oral squamous carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis 2:227
25. Skeen MJ, Miller MA, Shinnick TM, Ziegler, HK (1996) Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo. restimulation in vitro. and modulation by other cytokines. J Immunol 156:196
26. Sodhi A, Pai K, Singh RK, Singh SM (1990) Activation of human NK cells and monocytes with cisplatin in vitro, Int J Immunopharmacol 12:893
27. Tahara H, Zeh-III HJ, Storkus WJ, Pappo I, Watkins SC, Gubler WU, Wolf SF, Robbins PD, Lotze MT (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182
28. Timonen T, Saksela E (1977) A simplified isotope release assay for cell-mediated cytotoxicity against anchorage-dependent target cells. J Immunol Methods 18:123
29. Tripp CS, Wolf SF, Unanue ER (1993) Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90:3725
30. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87:581
31. Waal Malefyt R de, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209